Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

Moderna and Merck report that adding their personalized mRNA vaccine intismeran to Keytruda reduced the risk of melanoma recurrence or death by 42% over two years, compared with Keytruda and placebo. The reported two-year recurrence-free survival rates were 82% with the combination and 70% with the control treatment; further details on the results and their regulatory implications were not provided in the source material.

Moderna and Merck said their personalized mRNA cancer vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% when given with Keytruda, compared with Keytruda and placebo, in a Phase 3 trial. At two years, 82% of patients receiving the combination were alive without recurrence, versus 70% in the control group.

The companies’ reported results concern patients with resected melanoma, meaning their tumors had been surgically removed, who received the vaccine alongside Merck’s immunotherapy Keytruda. The comparison group received Keytruda and a placebo. The 42% figure describes a relative reduction in the risk of recurrence or death, not a 42-percentage-point increase in the share of patients who remained recurrence-free.

At the two-year assessment, recurrence-free survival was 82% for the intismeran-Keytruda group and 70% for the Keytruda-placebo group. The companies also reported a 38% reduction in the risk of distant metastasis or death with the combination. At the end of the reported assessment, 88.5% were alive without distant metastasis in the vaccine group, compared with 80% in the control group.

The findings were described in an announcement reported by Ars Technica. They are trial results reported by the companies; the source material does not provide the full study data, including the number of participants, confidence intervals, or detailed safety findings. The results therefore describe outcomes in this study population and do not establish that the vaccine benefits every person with melanoma.

A Possible Addition After Melanoma Surgery

The results matter because they suggest a personalized vaccine could add benefit to Keytruda after melanoma has been removed, a setting in which treatment aims to lower the chance that the cancer returns or spreads. The reported difference in two-year recurrence-free survival was 12 percentage points between the groups, while the companies’ headline figure expresses a relative risk reduction. Those measures describe the same trial from different angles and should not be confused.

The distant metastasis findings are also relevant: preventing melanoma from appearing in other parts of the body is a separate outcome from preventing any recurrence. However, the reported percentages do not show how long the benefit will last beyond the stated follow-up, nor do they by themselves answer how the treatment compares with other options or what risks it carries. Patients should not interpret the announcement as treatment guidance; decisions about melanoma care require discussion with an oncology professional.

How the Personalized Vaccine Is Made

Intismeran, also called mRNA-4157, is designed using genetic information from an individual patient’s tumor. According to the report, researchers compare the genetic sequences of cancer cells with those of healthy cells, then select cancer-specific mutations that may help the immune system identify the tumor. The synthetic mRNA can encode up to 34 mutations from that patient’s cancer.

The approach differs from a vaccine aimed at a shared target across many people: its contents are tailored to mutations found in a particular patient’s tumor. In the trial, the vaccine was paired with Keytruda, an immunotherapy made by Merck. The new announcement builds on earlier Phase 2 results. Ars Technica reported that a five-year Phase 2 trial showed a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk. The Phase 3 figures reported now are lower on those relative-risk measures, and the trial designs and follow-up periods should be considered when comparing them.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma, setting a new benchmark in the adjuvant setting and representing one of the most significant advances in melanoma treatment since the advent of immunotherapy.””

— Dean Li, president of Merck Research Laboratories, in the companies’ announcement

Full Trial Data Still Needed

The announcement details supplied in the source do not include the number of trial participants, statistical confidence intervals, the full follow-up schedule, or comprehensive safety results. Without those details, readers cannot assess the precision of the estimates or weigh the reported benefits against treatment risks. The report also does not establish whether regulators have reviewed the Phase 3 results or whether an application for approval has been submitted.

It is also unclear from the supplied material how the outcomes vary across patient subgroups, how long the apparent benefit persists, and whether the findings will be published in a peer-reviewed medical journal. The 42% risk reduction is a relative measure; it should not be read as meaning that 42% more patients avoided recurrence. The reported two-year group rates provide an absolute comparison for that particular endpoint and period.

Publication and Regulatory Steps

The next milestones to watch are release of the complete Phase 3 data, including safety results and statistical analyses, and any regulatory steps announced by Moderna or Merck. The source material does not specify a publication date, regulatory filing, or timetable for a decision. Until further information is available, the reported findings remain a company announcement about trial outcomes, not a new treatment approval.

Key Questions

What did the trial report?

Moderna and Merck reported that adding intismeran to Keytruda reduced the relative risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. The reported two-year recurrence-free survival rates were 82% and 70%, respectively.

Does the 42% figure mean 42% more patients avoided recurrence?

No. It is a reported relative reduction in risk, not a 42-percentage-point difference in patient outcomes. The companies reported recurrence-free survival of 82% in the vaccine group and 70% in the control group at two years.

What is intismeran?

Intismeran, also known as mRNA-4157, is a personalized mRNA vaccine designed around mutations identified in an individual patient’s tumor. The report says it can encode up to 34 selected cancer mutations and was tested with Keytruda.

Is the vaccine approved for melanoma treatment?

The source material does not say that intismeran has received regulatory approval or that a filing has been made. It reports Phase 3 trial findings; approval status and next regulatory steps remain unclear from the information provided.

Source: hn